Filing Details
- Accession Number:
- 0001437749-17-008637
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-05-10 16:30:19
- Reporting Period:
- 2017-05-08
- Filing Date:
- 2017-05-10
- Accepted Time:
- 2017-05-10 16:30:19
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1586049 | Oxford Immunotec Global Plc | OXFD | In Vitro & In Vivo Diagnostic Substances (2835) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1592272 | R. Jeff Schroeder | C/O Oxford Immunotec Global Plc 94C Innovation Drive Abingdon, Oxfordshire X0 OX14 4RZ | Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Disposition | 2017-05-08 | 17,603 | $14.30 | 149,544 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2017-05-09 | 22,397 | $14.01 | 127,147 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The price reported for the sales on May 8, 2017 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.05 to $14.455 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
- The price reported for the sales on May 9, 2017 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.055 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
Billionaire Hedge Funds
